Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 3, 2010, Pages 537-540

  Yasui Furukori, Norio ^a   Saito, Manabu ^a   Nakagami, Taku ^a,b   Sugawara, Norio ^a,c   Sato, Yasushi ^a,c   Tsuchimine, Shoko ^a   Furukori, Hanako ^d   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Hirosaki Aiseikai Hospital   (Japan)

^c Ohdate City Hospital   (Japan)

^d Kuroishi General Hospital   (Japan)

Author keywords

Gender; Olanzapine; Prolactin; Risperidone

Indexed keywords

BIPERIDEN; FLUNITRAZEPAM; OLANZAPINE; PROLACTIN; RISPERIDONE; SENNOSIDE;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PREDICTION; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; PROLACTIN; RISPERIDONE; SCHIZOPHRENIA; SEX CHARACTERISTICS; STATISTICS AS TOPIC; TIME FACTORS;

EID: 77949653794     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.02.014     Document Type: Article

References (25)

1. D'Arrigo C., Migliardi G., Santoro V., Spina E. Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 2006, 28:388-393.
2. Harnryd C., Bjerkenstedt L., Gullberg B., Oxenstierna G., Sedvall G., Wiesel F.A. Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr Scand 1984, 311:75-92. Suppl.
3. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001, 158:360-369.
4. Kinon B.J., Gilmore J.A., Liu H., Halbreich U.M. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003, 28(Suppl 2):69-82.
5. Kinon B.J., Ahl J., Liu-Seifert H., Maguire G.A. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006, 31:577-588.
6. Kleinberg D.L., Davis J.M., de Coster R., Van Baelen B., Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999, 19:57-61.
7. Linkowski P., Hubain P., von Frenckell R., Mendlewicz J. Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatry Neurol Sci 1984, 234:231-236.
8. Meaney A.M., Smith S., Howes O.D., O'Brien M., Murray R.M., O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004, 184:503-508.
9. Meltzer H.Y., Busch D.A., Fang V.S. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 1983, 9:271-283.
10. Migliardi G., Spina E., D'Arrigo C., Gagliano A., Germanò E., Siracusano R., et al. Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1496-1501.
11. Nakagami T., Yasui-Furukori N., Saito M., Tateishi T., Kaneko S. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 2005, 78:43-51.
12. Nordstrom A.L., Farde L. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 1998, 18:305-310.
13. Otani K., Kondo T., Kaneko S., Ishida M., Fukushima Y. Correlation between prolactin response to zotepine in schizophrenic patients. Hum Psycopharmacol 1993, 8:35-39.
14. Otani K., Kondo T., Yausi N., Suzuki A., Furukori H., Kaneko S., et al. Prolactin response to nemonapride, a new antipsychotic drug, in schizophrenic patients. Hum Psycopharmacol 1997, 12:591-594.
15. Petty R.G. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999, 35:S67-S73. Suppl.
16. Rubin R.T. Prolactin and schizophrenia. Psychopharmacology: the third generation of progress 1987, 803-808. Raven Press, New York. H.Y. Meltzer (Ed.).
17. Sawamura T., Suzuki Y., Fukui N., Sugai T., Someya T. Gender differences in prolactin elevation induced by olanzapine in Japanese drug-naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1511-1514.
18. Schotte A., Bonaventure P., Janssen P.F.M., Leysen J.E. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotic hitherto used. Jpn J Pharmacol 1995, 69:399-412.
19. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002, 47:27-38.
20. Seeman P., Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998, 3:123-134.
21. Turrone P., Kapur S., Seeman M.V., Flint A.J. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002, 159:1608-1609.
22. Yasui N., Kondo T., Otani K., Ishida M., Mihara K., Suzuki A., et al. Prolactin response to bromperidol treatment in schizophrenic patients. Pharmacol Toxicol 1998, 82:153-156.
23. Yasui-Furukori N., Kondo T., Suzuki A., Mihara K., Tokinaga N., Inoue Y., et al. Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol. Schizophr Res 2001, 52:139-142.
24. Yasui-Furukori N., Tsuchimine S., Saito M., Nakagami T., Sato Y., Kaneko S. Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1230-1234.
25. Yasui-Furukori N., Saito M., Tsuchimine S., Nakagami T., Sato Y., Sugawara N., et al. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1491-1495.